Reshape Lifesciences Inc (NAS:RSLS)
$ 5.915 -0.105 (-1.74%) Market Cap: 3.00 Mil Enterprise Value: 2.21 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 64/100

Q4 2021 ReShape Lifesciences Inc Earnings Call Transcript

Mar 28, 2022 / 09:30PM GMT
Release Date Price: $3915 (-4.26%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the ReShape Lifesciences Fourth Quarter 2021 Earnings Conference Call. (Operator Instructions)

Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to turn the conference over to your speaker for today, Michael Miller, Rx Communications. You may begin.

Michael Miller;Rx Communications Group;Senior Vice President
LLC;Investor Relations,

Good afternoon, and thank you for joining the Year-End 2021 ReShape Life Sciences Earnings Conference Call. I'm pleased to be joined by Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences Inc, who will provide an overview of the company's activity during 2021 and milestones to date; Tom Stankovich, Chief Financial Officer of ReShape, will then review the financial results for the year, after which we will open up the call to a question-and-answer session.

As a reminder, this conference call, as well as ReShape Lifesciences' SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot